Anzeige
Mehr »
Dienstag, 02.09.2025 - Börsentäglich über 12.000 News
Milliardenmarkt Multiple Sklerose: Neue Therapieform könnte alles verändern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCDR | ISIN: US20451W1018 | Ticker-Symbol: 5Y6
Tradegate
02.09.25 | 15:57
3,900 Euro
+3,17 % +0,120
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
COMPASS PATHWAYS PLC ADR Chart 1 Jahr
5-Tage-Chart
COMPASS PATHWAYS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
3,8403,96016:49
3,8603,92016:49

Aktuelle News zur COMPASS PATHWAYS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:36Compass Pathfinder Limited: Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder148Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms...
► Artikel lesen
07:00Deals im Milliarden-Markt für Psychedelika: AbbVie, Atai Life Sciences, Neural Therapeutics
MiCompass Pathfinder Limited: Compass Pathways to Participate in Four Investor Conferences in September309Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate...
► Artikel lesen
05.08.Compass Pathfinder Limited: Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA404Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Management will participate...
► Artikel lesen
COMPASS PATHWAYS Aktie jetzt für 0€ handeln
31.07.Compass Pathways outlines FDA engagement and accelerated pathways for COMP360 in TRD while advancing PTSD program13
31.07.Compass Pathfinder: Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights376Positive primary endpoint achieved in first COMP360 Phase 3 trial with high statistical significance, clinically meaningful reduction in depression at 6 weeks, and no unexpected safety findings...
► Artikel lesen
31.07.COMPASS Pathways plc - 10-Q, Quarterly Report7
29.07.Compass Pathways appoints former GW Pharmaceuticals CEO to board14
29.07.COMPASS Pathways plc - 8-K, Current Report3
22.07.Compass Pathfinder Limited: Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025278Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based...
► Artikel lesen
24.06.Compass Pathways stock holds Buy rating on positive depression trial54
24.06.Kursziel für Compass Pathways von BTIG auf 7 US-Dollar gesenkt66
24.06.Compass Pathways price target lowered to $7 by BTIG on drug concerns9
23.06.Why Is Compass Pathways Stock Trading Lower On Monday?35
23.06.Compass Pathways meldet positive Ergebnisse der Phase-3-Studie für COMP360 bei Depression36
23.06.Evercore ISI downgrades Compass Pathways stock on durability concerns10
23.06.Compass Pathways stock slip as psilocybin depression trial falls short of expectations10
23.06.Compass Pathways stock plunges after Phase 3 trial results4
23.06.Compass Pathways-Aktie stürzt nach Ergebnissen der Phase-3-Studie ab25
23.06.Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session24
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4